AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Small RNA 2'-O-methyltransferase

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q5T8I9

UPID:

HENMT_HUMAN

Alternative names:

HEN1 methyltransferase homolog 1

Alternative UPACC:

Q5T8I9; A8MRR6; B1AM16; B1AM17; Q96EJ7; Q96NN0

Background:

Small RNA 2'-O-methyltransferase, also known as HEN1 methyltransferase homolog 1, plays a pivotal role in the biogenesis of piRNAs. These piRNAs, ranging from 24 to 30 nucleotides, originate from transposons and repeated sequence elements through a Dicer-independent mechanism. The enzyme's methyltransferase activity adds a 2'-O-methyl group at the 3'-end of piRNAs, crucial for their stability by protecting them from uridylation and degradation. This stabilization is vital for gametogenesis, highlighting the enzyme's significance in reproductive biology.

Therapeutic significance:

Understanding the role of Small RNA 2'-O-methyltransferase could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.